Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor.

Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor.

The DDR1 receptor tyrosine kinase is activated by matrix collagens and has been implicated in numerous cellular functions such as proliferation, differentiation, adhesion, migration, and invasion. Here we report the discovery of a potent and selective DDR1 inhibitor, DDR1-IN-1, and present the 2.2 Å...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs:	Kim, H, Tan, L, Weisberg, E, Liu, F, Canning, P, Choi, H, Ezell, SA, Wu, H, Zhao, Z, Wang, J, Mandinova, A, Griffin, J, Bullock, A, Liu, Q, Lee, S, Gray, N
Formaat:	Journal article
Taal:	English
Gepubliceerd in:	2013

Gelijkaardige items

Correction to Discovery of a Potent and Selective DDR1 Receptor Tyrosine Kinase Inhibitor.
door: Kim, H, et al.
Gepubliceerd in: (2014)

Structural mechanisms determining inhibition of the collagen receptor DDR1 by selective and multi-targeted type II kinase inhibitors
door: Canning, P, et al.
Gepubliceerd in: (2014)

Structural mechanisms determining inhibition of the collagen receptor DDR1 by selective and multi-targeted type II kinase inhibitors.
door: Canning, P, et al.
Gepubliceerd in: (2014)

Tyrosine Kinase Inhibitors Display Potent Activity against Cryptosporidium parvum
door: Maria G. Nava, et al.
Gepubliceerd in: (2023-02-01)

New potent dual inhibitors of CK2 and Pim kinases: discovery and structural insights.
door: López-Ramos, M, et al.
Gepubliceerd in: (2010)

New potent dual inhibitors of CK2 and Pim kinases: discovery and structural insights.
door: López-Ramos, M, et al.
Gepubliceerd in: (2010)

Inhibitors of Discoidin Domain Receptor (DDR) Kinases for Cancer and Inflammation
door: William A. Denny, et al.
Gepubliceerd in: (2021-11-01)

Editorial: Discovery of EGFR tyrosine kinase inhibitors for cancer treatment
door: Panupong Mahalapbutr, et al.
Gepubliceerd in: (2024-02-01)

Discovery of Novel Naphthoquinone–Chalcone Hybrids as Potent FGFR1 Tyrosine Kinase Inhibitors: Synthesis, Biological Evaluation, and Molecular Modeling
door: Ronnakorn Leechaisit, et al.
Gepubliceerd in: (2023-08-01)

Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.
door: Patrice Dubreuil, et al.
Gepubliceerd in: (2009-09-01)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
door: Xu H, et al.
Gepubliceerd in: (2019-07-01)

Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors
door: Sudarshan R Iyer, et al.
Gepubliceerd in: (2023-10-01)

Recent Advances in Discovery of New Tyrosine Kinase Inhibitors Using Computational Methods
door: Vesna Rastija
Gepubliceerd in: (2019-08-01)

Bioactive Phytoconstituents as Potent Inhibitors of Tyrosine-Protein Kinase Yes (YES1): Implications in Anticancer Therapeutics
door: Chunmin Yang, et al.
Gepubliceerd in: (2022-05-01)

Small-molecule inhibitors of the c-Fes protein-tyrosine kinase.
door: Hellwig, S, et al.
Gepubliceerd in: (2012)

New potent dual inhibitors of CK2 and Pim kinases: discovery and structural insights (September, pg 3175, 2010)
door: Lopez-Ramos, M, et al.
Gepubliceerd in: (2011)

Kindlin-3 inactivation mediates melanoma agressiveness through crosstalk with the collagen-activated tyrosine kinase receptor DDR1
door: C. Reger de Moura, et al.
Gepubliceerd in: (2024-01-01)

Selective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cells.
door: Ellen Weisberg, et al.
Gepubliceerd in: (2013-01-01)

First‐in‐human study of deucravacitinib: A selective, potent, allosteric small‐molecule inhibitor of tyrosine kinase 2
door: Ian M. Catlett, et al.
Gepubliceerd in: (2023-01-01)

TYROSINE KINASE INHIBITORS AND INTERFERON
door: Maria Dimou, et al.
Gepubliceerd in: (2014-01-01)

TYROSINE KINASE INHIBITORS AND PREGNANCY
door: Elisabetta Abruzzese, et al.
Gepubliceerd in: (2014-04-01)

Second-generation inhibitors of Bruton tyrosine kinase
door: Jingjing Wu, et al.
Gepubliceerd in: (2016-09-01)

Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and IGF-1R
door: Cornelius Hempel, et al.
Gepubliceerd in: (2017-01-01)

Discovery of Novel N-Substituted Prolinamido Indazoles as Potent Rho Kinase Inhibitors and Vasorelaxation Agents
door: Yangyang Yao, et al.
Gepubliceerd in: (2017-10-01)

Tyrosine Kinase Inhibitors in Pulmonary Vascular Disease
door: John J. Ryan, MD
Gepubliceerd in: (2016-12-01)

Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery?
door: Zhao, Z, et al.
Gepubliceerd in: (2014)

The two facets of receptor tyrosine kinase in cardiovascular calcification—can tyrosine kinase inhibitors benefit cardiovascular system?
door: Ainun Nizar Masbuchin, et al.
Gepubliceerd in: (2022-09-01)

Tyrosine kinase inhibitor Tofacitinib. Safety issues
door: G. V. Lukina, et al.
Gepubliceerd in: (2015-12-01)

Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma
door: Huang JT, et al.
Gepubliceerd in: (2022-11-01)

Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth.
door: Mark C Weir, et al.
Gepubliceerd in: (2017-01-01)

miR-494 in Extracellular Vesicles as a Potent Biomarker of Chronic Myeloid Leukemia Treatment with Tyrosine Kinase Inhibitors
door: Tatsuki Shibuta, et al.
Gepubliceerd in: (2022-06-01)

Vorolanib, a novel tyrosine receptor kinase receptor inhibitor with potent preclinical anti-angiogenic and anti-tumor activity
door: Chris Liang, et al.
Gepubliceerd in: (2022-03-01)

Mechanism and treatment of diarrhea associated with tyrosine kinase inhibitors
door: Jiangnan Liu, et al.
Gepubliceerd in: (2024-03-01)

Acquired Hypothyroidism in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors
door: Wu J, et al.
Gepubliceerd in: (2020-09-01)

Integrating machine learning and structure-based approaches for repurposing potent tyrosine protein kinase Src inhibitors to treat inflammatory disorders
door: Muhammad Waleed Iqbal, et al.
Gepubliceerd in: (2025-01-01)

Inhaled tyrosine kinase inhibitors for pulmonary hypertension: a possible future treatment
door: Pitsiou G, et al.
Gepubliceerd in: (2014-10-01)

509 Potent and selective inhibition Of AXL receptor tyrosine kinase for the treatment of cancer
door: Matthew Walters, et al.
Gepubliceerd in: (2020-11-01)

Activation of transmembrane receptor tyrosine kinase DDR1-STAT3 cascade by extracellular matrix remodeling promotes liver metastatic colonization in uveal melanoma
door: Wei Dai, et al.
Gepubliceerd in: (2021-05-01)

Tetrahydroisoquinoline-7-carboxamide derivatives as new selective discoidin domain receptor 1 (DDR1) inhibitors
door: Bullock, A, et al.
Gepubliceerd in: (2017)

Receptor Tyrosine Kinases and Inhibitors in Lung Cancer
door: Evan Pisick, et al.
Gepubliceerd in: (2004-01-01)